LG Balakrishnan & Bros Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 28, 2025, 2:22 pm

Competitors of LG Balakrishnan & Bros Ltd

All Competitor Stocks of LG Balakrishnan & Bros Ltd

Quarterly Result

Last Updated: August 1, 2025, 6:00 pm

Below is a detailed analysis of the quarterly data for LG Balakrishnan & Bros Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 657.00 Cr.. The value appears to be declining and may need further review. It has decreased from 669.00 Cr. (Mar 2025) to 657.00 Cr., marking a decrease of 12.00 Cr..
• For Expenses, as of Jun 2025, the value is 560.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 567.00 Cr. (Mar 2025) to 560.00 Cr., marking a decrease of 7.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 97.00 Cr.. The value appears to be declining and may need further review. It has decreased from 102.00 Cr. (Mar 2025) to 97.00 Cr., marking a decrease of 5.00 Cr..
• For OPM %, as of Jun 2025, the value is 15.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00%.
• For Other Income, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 4.00 Cr..
• For Interest, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 26.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 25.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 91.00 Cr.. The value appears to be declining and may need further review. It has decreased from 102.00 Cr. (Mar 2025) to 91.00 Cr., marking a decrease of 11.00 Cr..
• For Tax %, as of Jun 2025, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 18.00% (Mar 2025) to 27.00%, marking an increase of 9.00%.
• For Net Profit, as of Jun 2025, the value is 67.00 Cr.. The value appears to be declining and may need further review. It has decreased from 84.00 Cr. (Mar 2025) to 67.00 Cr., marking a decrease of 17.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 21.00. The value appears to be declining and may need further review. It has decreased from 26.35 (Mar 2025) to 21.00, marking a decrease of 5.35.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:57 am

Growth

Last Updated: September 5, 2025, 9:40 am

Balance Sheet

Last Updated: August 11, 2025, 2:15 pm

Below is a detailed analysis of the balance sheet data for LG Balakrishnan & Bros Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 31.00 Cr. (Mar 2024) to 32.00 Cr., marking an increase of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,873.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,610.00 Cr. (Mar 2024) to 1,873.00 Cr., marking an increase of 263.00 Cr..
• For Borrowings, as of Mar 2025, the value is 157.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 115.00 Cr. (Mar 2024) to 157.00 Cr., marking an increase of 42.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 508.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 480.00 Cr. (Mar 2024) to 508.00 Cr., marking an increase of 28.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,570.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,237.00 Cr. (Mar 2024) to 2,570.00 Cr., marking an increase of 333.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 812.00 Cr.. The value appears strong and on an upward trend. It has increased from 573.00 Cr. (Mar 2024) to 812.00 Cr., marking an increase of 239.00 Cr..
• For CWIP, as of Mar 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 47.00 Cr. (Mar 2024) to 22.00 Cr., marking a decrease of 25.00 Cr..
• For Investments, as of Mar 2025, the value is 153.00 Cr.. The value appears to be declining and may need further review. It has decreased from 176.00 Cr. (Mar 2024) to 153.00 Cr., marking a decrease of 23.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,582.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,441.00 Cr. (Mar 2024) to 1,582.00 Cr., marking an increase of 141.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,570.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,237.00 Cr. (Mar 2024) to 2,570.00 Cr., marking an increase of 333.00 Cr..

Notably, the Reserves (1,873.00 Cr.) exceed the Borrowings (157.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for LG Balakrishnan & Bros Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 95.44. This value is within the healthy range. It has increased from 86.44 (Mar 24) to 95.44, marking an increase of 9.00.
• For Diluted EPS (Rs.), as of Mar 25, the value is 95.44. This value is within the healthy range. It has increased from 86.44 (Mar 24) to 95.44, marking an increase of 9.00.
• For Cash EPS (Rs.), as of Mar 25, the value is 123.42. This value is within the healthy range. It has increased from 111.32 (Mar 24) to 123.42, marking an increase of 12.10.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 597.16. It has increased from 523.60 (Mar 24) to 597.16, marking an increase of 73.56.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 597.16. It has increased from 523.60 (Mar 24) to 597.16, marking an increase of 73.56.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 808.43. It has increased from 747.33 (Mar 24) to 808.43, marking an increase of 61.10.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 147.39. This value is within the healthy range. It has increased from 141.41 (Mar 24) to 147.39, marking an increase of 5.98.
• For PBIT / Share (Rs.), as of Mar 25, the value is 118.69. This value is within the healthy range. It has increased from 116.58 (Mar 24) to 118.69, marking an increase of 2.11.
• For PBT / Share (Rs.), as of Mar 25, the value is 122.72. This value is within the healthy range. It has increased from 116.18 (Mar 24) to 122.72, marking an increase of 6.54.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 94.72. This value is within the healthy range. It has increased from 86.48 (Mar 24) to 94.72, marking an increase of 8.24.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 94.73. This value is within the healthy range. It has increased from 86.44 (Mar 24) to 94.73, marking an increase of 8.29.
• For PBDIT Margin (%), as of Mar 25, the value is 18.23. This value is within the healthy range. It has decreased from 18.92 (Mar 24) to 18.23, marking a decrease of 0.69.
• For PBIT Margin (%), as of Mar 25, the value is 14.68. This value is within the healthy range. It has decreased from 15.60 (Mar 24) to 14.68, marking a decrease of 0.92.
• For PBT Margin (%), as of Mar 25, the value is 15.18. This value is within the healthy range. It has decreased from 15.54 (Mar 24) to 15.18, marking a decrease of 0.36.
• For Net Profit Margin (%), as of Mar 25, the value is 11.71. This value exceeds the healthy maximum of 10. It has increased from 11.57 (Mar 24) to 11.71, marking an increase of 0.14.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.71. This value is within the healthy range. It has increased from 11.56 (Mar 24) to 11.71, marking an increase of 0.15.
• For Return on Networth / Equity (%), as of Mar 25, the value is 15.86. This value is within the healthy range. It has decreased from 16.53 (Mar 24) to 15.86, marking a decrease of 0.67.
• For Return on Capital Employeed (%), as of Mar 25, the value is 18.96. This value is within the healthy range. It has decreased from 21.42 (Mar 24) to 18.96, marking a decrease of 2.46.
• For Return On Assets (%), as of Mar 25, the value is 11.75. This value is within the healthy range. It has decreased from 12.13 (Mar 24) to 11.75, marking a decrease of 0.38.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.07. This value is within the healthy range. It has increased from 0.06 (Mar 24) to 0.07, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.07. It has decreased from 1.14 (Mar 24) to 1.07, marking a decrease of 0.07.
• For Current Ratio (X), as of Mar 25, the value is 2.19. This value is within the healthy range. It has increased from 2.10 (Mar 24) to 2.19, marking an increase of 0.09.
• For Quick Ratio (X), as of Mar 25, the value is 1.44. This value is within the healthy range. It has increased from 1.37 (Mar 24) to 1.44, marking an increase of 0.07.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.28. This value is within the healthy range. It has increased from 2.67 (Mar 24) to 6.28, marking an increase of 3.61.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 18.70. This value is below the healthy minimum of 20. It has increased from 18.51 (Mar 24) to 18.70, marking an increase of 0.19.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 14.35. This value is below the healthy minimum of 20. It has decreased from 14.38 (Mar 24) to 14.35, marking a decrease of 0.03.
• For Earning Retention Ratio (%), as of Mar 25, the value is 81.30. This value exceeds the healthy maximum of 70. It has decreased from 81.49 (Mar 24) to 81.30, marking a decrease of 0.19.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 85.65. This value exceeds the healthy maximum of 70. It has increased from 85.62 (Mar 24) to 85.65, marking an increase of 0.03.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 46.18. This value is within the healthy range. It has decreased from 54.96 (Mar 24) to 46.18, marking a decrease of 8.78.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 28.41. This value is within the healthy range. It has decreased from 33.77 (Mar 24) to 28.41, marking a decrease of 5.36.
• For Enterprise Value (Cr.), as of Mar 25, the value is 3,499.92. It has decreased from 3,724.41 (Mar 24) to 3,499.92, marking a decrease of 224.49.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.36. This value is within the healthy range. It has decreased from 1.59 (Mar 24) to 1.36, marking a decrease of 0.23.
• For EV / EBITDA (X), as of Mar 25, the value is 7.45. This value is within the healthy range. It has decreased from 8.39 (Mar 24) to 7.45, marking a decrease of 0.94.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.47. This value is within the healthy range. It has decreased from 1.70 (Mar 24) to 1.47, marking a decrease of 0.23.
• For Retention Ratios (%), as of Mar 25, the value is 81.29. This value exceeds the healthy maximum of 70. It has decreased from 81.48 (Mar 24) to 81.29, marking a decrease of 0.19.
• For Price / BV (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has decreased from 2.43 (Mar 24) to 1.98, marking a decrease of 0.45.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.47. This value is within the healthy range. It has decreased from 1.70 (Mar 24) to 1.47, marking a decrease of 0.23.
• For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.07, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness